Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cypralis, Janssen in Neurodegenerative Pact | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

Cypralis, Janssen in Neurodegenerative Pact

Aims to develop new cyclophilin inhibitors for neurodegenerative diseases

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Cypralis has entered into a collaboration with Janssen Pharmaceuticals Inc., facilitated by Johnson & Johnson Innovation, to develop new cyclophilin inhibitors for neurodegenerative diseases. The terms were not disclosed.
 
Cypralis focuses on the discovery of therapeutics for the modulation of peptidyl-prolyl isomerases (PPIases). Cyclophilin inhibitors on the market or in development are non-selective between the four commonly screened cyclophilin isoforms A, B, C and D. Cypralis and Janssen are undertaking a joint research program to generate a new class of CNS penetrant, selective inhibitors of cyclophilin D to target degenerative diseases including CNS degeneration. The medicinal chemistry and PPIase screening will be sub-contracted to Selcia Ltd.
 
Simon Kerr, chief executive officer of Cypralis said, “We are delighted to be collaborating with Janssen in order to develop a novel class of cyclophilin D inhibitors. We are hopeful that this effort will pave the way towards a new approach to the treatment of neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics